PT - JOURNAL ARTICLE AU - Lachlan E. McInnes AU - Carleen Cullinane AU - Peter D. Roselt AU - Susan Jackson AU - Benjamin J. Blyth AU - Ellen M. van Dam AU - Nicholas A. Zia AU - Matthew J. Harris AU - Rodney J. Hicks AU - Paul S. Donnelly TI - Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with <sup>67</sup>Cu AID - 10.2967/jnumed.120.251579 DP - 2021 Jun 01 TA - Journal of Nuclear Medicine PG - 829--832 VI - 62 IP - 6 4099 - http://jnm.snmjournals.org/content/62/6/829.short 4100 - http://jnm.snmjournals.org/content/62/6/829.full SO - J Nucl Med2021 Jun 01; 62 AB - Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&amp;T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.